News Image

Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation.

By Mill Chart

Last update: Mar 7, 2024

Discover CORCEPT THERAPEUTICS INC (NASDAQ:CORT), an undervalued growth gem identified by our stock screener. NASDAQ:CORT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability. What's more, it retains an appealing valuation. We'll break it down further.

How We Gauge Growth for NASDAQ:CORT

To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:CORT has achieved a 7 out of 10:

  • The Revenue has grown by 20.03% in the past year. This is a very strong growth!
  • Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 13.94% on average per year.
  • Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 28.28% on average per year.
  • CORT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.93% yearly.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Valuation Examination for NASDAQ:CORT

ChartMill assigns a proprietary Valuation Rating to each stock. The score is computed by evaluating various valuation aspects, like price to earnings and free cash flow, both absolutely as relative to the market and industry. NASDAQ:CORT was assigned a score of 6 for valuation:

  • Based on the Price/Earnings ratio, CORT is valued cheaply inside the industry as 83.58% of the companies are valued more expensively.
  • CORT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 79.60% of the companies in the same industry.
  • 81.59% of the companies in the same industry are more expensive than CORT, based on the Enterprise Value to EBITDA ratio.
  • CORT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CORT is cheaper than 84.08% of the companies in the same industry.
  • The excellent profitability rating of CORT may justify a higher PE ratio.
  • CORT's earnings are expected to grow with 20.59% in the coming years. This may justify a more expensive valuation.

Health Assessment of NASDAQ:CORT

ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:CORT, the assigned 9 for health provides valuable insights:

  • An Altman-Z score of 15.40 indicates that CORT is not in any danger for bankruptcy at the moment.
  • CORT's Altman-Z score of 15.40 is amongst the best of the industry. CORT outperforms 90.05% of its industry peers.
  • CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • CORT has a Current Ratio of 4.39. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
  • CORT has a Quick Ratio of 4.31. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 4.31, CORT is doing good in the industry, outperforming 60.20% of the companies in the same industry.

A Closer Look at Profitability for NASDAQ:CORT

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:CORT, the assigned 8 is a significant indicator of profitability:

  • Looking at the Return On Assets, with a value of 17.08%, CORT belongs to the top of the industry, outperforming 96.02% of the companies in the same industry.
  • With an excellent Return On Equity value of 20.95%, CORT belongs to the best of the industry, outperforming 92.54% of the companies in the same industry.
  • CORT has a better Return On Invested Capital (17.91%) than 94.03% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CORT is above the industry average of 17.03%.
  • CORT's Profit Margin of 22.01% is amongst the best of the industry. CORT outperforms 94.03% of its industry peers.
  • Looking at the Operating Margin, with a value of 22.26%, CORT belongs to the top of the industry, outperforming 89.55% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 98.66%, CORT belongs to the top of the industry, outperforming 97.51% of the companies in the same industry.

More Affordable Growth stocks can be found in our Affordable Growth screener.

Our latest full fundamental report of CORT contains the most current fundamental analsysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (4/22/2024, 7:00:01 PM)

After market: 22.87 +0.57 (+2.56%)

22.3

-0.65 (-2.83%)

CORT News

News Image16 hours ago - Market News VideoNotable Monday Option Activity: RIOT, SIG, CORT
News Imagea day ago - Corcept Therapeutics IncorporatedCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
News Image4 days ago - ChartmillWhile growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

News Image8 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
News Image8 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Image15 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
News Image22 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
News Image22 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Imagea month ago - Market News VideoNotable Monday Option Activity: GME, LULU, CORT
News Image2 months ago - Seeking AlphaCorcept Therapeutics GAAP EPS of $0.28 beats by $0.02, revenue of $135.4M beats by $6.1M (NASDAQ:CORT)

Corcept Therapeutics reports Q4 2023 financial results, with GAAP EPS of $0.28 beating expectations by $0.02 and revenue of $135.4M surpassing estimates by...

News Image2 months ago - Corcept Therapeutics IncorporatedCorcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
News Image2 months ago - Corcept Therapeutics IncorporatedCorcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

CORT Links
Follow us for more